PMID- 16464954
OWN - NLM
STAT- MEDLINE
DCOM- 20060501
LR  - 20140729
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 91
IP  - 4
DP  - 2006 Apr
TI  - High serum levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I) 
      during high-dose GH treatment in short children born small for gestational age.
PG  - 1390-6
AB  - CONTEXT: Epidemiological studies have indicated that high serum levels of GH and 
      IGF-I are associated with long-term risks. OBJECTIVE: The objective of the study 
      was to evaluate the changes in serum levels of GH during overnight profiles, 
      IGF-I, and IGF binding protein 3 (IGFBP-3) in short small for gestational age 
      (SGA) children during GH treatment with two doses. PATIENTS: Thirty-six 
      prepubertal short SGA children were the subjects of this study. INTERVENTION: 
      Subjects received 1 (group A) or 2 (group B) mg GH/m(2).d. MAIN OUTCOME MEASURES: 
      At baseline and after 6 months of GH treatment, overnight GH profiles were 
      performed, and serum IGF-I and IGFBP-3 levels were measured. RESULTS: After 6 
      months, group B had significantly higher GH levels during the profile (mean, 
      maximum, and area under the curve above zero line) than group A (P < 0.009). In 
      group B, maximum GH levels increased from 43.9-161 mU/liter (P < 0.0002), and in 
      group A, from 57.2-104 mU/liter (P = 0.002). During the profile (i.e. 12 h per 
      day), children of group B had mean GH levels of 64.4 vs. 34.8 mU/liter in group A 
      (P = 0.001). The IGF-I and IGF-I to IGFBP-3 ratio sd scores increased 
      significantly in both groups, but were higher in group B than A [1.5 vs. 0.2 (P = 
      0.002) and 1.4 vs. 0.3 (P = 0.007), respectively]. In group B, 74% of the 
      children had IGF-I levels in the highest quintile during GH treatment compared 
      with 19% in group A. CONCLUSION: Our study shows that high-dose GH treatment in 
      short SGA children results in high serum GH and IGF-I levels in most children. We 
      recommend monitoring IGF-I levels during GH therapy to ensure that these remain 
      within the normal range.
FAU - van Dijk, Marije
AU  - van Dijk M
AD  - Department of Pediatrics, Division of Endocrinology, Erasmus University Medical 
      Center, Sophia Children's Hospital sk-0152, P.O. Box 2060, 3000 CB Rotterdam, The 
      Netherlands. m.vandijk.1@erasmusmc.nl
FAU - Mulder, Paul
AU  - Mulder P
FAU - Houdijk, Mieke
AU  - Houdijk M
FAU - Mulder, Jaap
AU  - Mulder J
FAU - Noordam, Kees
AU  - Noordam K
FAU - Odink, Roelof J
AU  - Odink RJ
FAU - Rongen-Westerlaken, Ciska
AU  - Rongen-Westerlaken C
FAU - Voorhoeve, Paul
AU  - Voorhoeve P
FAU - Waelkens, Johan
AU  - Waelkens J
FAU - Stokvis-Brantsma, Jet
AU  - Stokvis-Brantsma J
FAU - Hokken-Koelega, Anita
AU  - Hokken-Koelega A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060207
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Area Under Curve
MH  - Body Height/*physiology
MH  - Child
MH  - Female
MH  - Growth/drug effects/physiology
MH  - Growth Hormone/*therapeutic use
MH  - Human Growth Hormone/*blood
MH  - Humans
MH  - Infant, Newborn
MH  - *Infant, Small for Gestational Age
MH  - Insulin-Like Growth Factor Binding Protein 3/blood
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Male
EDAT- 2006/02/09 09:00
MHDA- 2006/05/02 09:00
CRDT- 2006/02/09 09:00
PHST- 2006/02/09 09:00 [pubmed]
PHST- 2006/05/02 09:00 [medline]
PHST- 2006/02/09 09:00 [entrez]
AID - jc.2005-1663 [pii]
AID - 10.1210/jc.2005-1663 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2006 Apr;91(4):1390-6. doi: 10.1210/jc.2005-1663. Epub 
      2006 Feb 7.